Trials / Active Not Recruiting
Active Not RecruitingNCT04877613
GFRα4 CAR T Cells in MTC Patients
Phase I Trial of GFRα4 CAR T Cells in Adult Patients With Recurrent or Metastatic Medullary Thyroid Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | single dose of CART-GFRa4 cells | Intravenous infusion of lentiviral transduced autologous T cells that have been engineered to express an extracellular single chain antibody (scFv) with specificity towards GFRa4 with fludarabine and cyclophosphamide. |
| DRUG | Fludarabine | Lymphodepletion |
| DRUG | Cyclophosphamide | Lymphodepletion |
Timeline
- Start date
- 2021-08-19
- Primary completion
- 2039-06-01
- Completion
- 2039-06-01
- First posted
- 2021-05-07
- Last updated
- 2025-07-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04877613. Inclusion in this directory is not an endorsement.